StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
ILMNBullishEarningsnews
High materiality8/10

Illumina lifts FY2026 guidance on strong Q3 momentum and NovaSeq X demand

Oct 29, 2026, 4:24 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong Q3 beat, guidance raised across revenue and EPS, and evidence of AI/ecosystem upside likely to lift near-term sentiment; risks include China exposure and tariff commentary.

AI summary

What happened, with direct paths to the underlying reporting

Illumina reported solid Q3 2026 results with $1.129B revenue and raised full-year guidance on robust NovaSeq X placements and healthy clinical demand. The upgrade lifts FY revenue to $4.64-$4.66B and non-GAAP EPS to $5.40-$5.45, aided by tariff refunds affecting non-GAAP measures. The company reiterates AI and ecosystem expansion as core value drivers, while China ROW exposure remains a regulatory risk.

  • Q3 2026 revenue $1.129B (GAAP); non-GAAP $1.129B; excluding tariffs $1.166B.
  • FY2026 guidance raised: revenue $4.64-$4.66B; non-GAAP EPS $5.40-$5.45.
  • NovaSeq X placements and solid clinical demand drive upside; ROW growth strong; China risk noted.
  • Tariff refunds boost non-GAAP metrics modestly; cash and FCF remain solid.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event